Skip to main content

Rabbit Recombinant Monoclonal Insulin degrading enzyme / IDE antibody - conjugated to HRP. Suitable for WB and reacts with Human samples.

Be the first to review this product! Submit a review

Images

Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (AB201836), expandable thumbnail
  • Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (AB201836), expandable thumbnail

Key facts

Isotype

IgG

Host species

Rabbit

Conjugation

HRP

Storage buffer

pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA

Form

Liquid

Clonality

Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WB
Human
Tested
Mouse
Predicted
Rat
Predicted

Tested
Tested

Species

Human

Dilution info

1/5000

Notes

-

Predicted
Predicted

Species

Mouse, Rat

Dilution info

-

Notes

-

Associated Products

Select an associated product type

4 products for Alternative Product

1 product for Alternative Version

Target data

Function

Plays a role in the cellular breakdown of insulin, APP peptides, IAPP peptides, natriuretic peptides, glucagon, bradykinin, kallidin, and other peptides, and thereby plays a role in intercellular peptide signaling (PubMed:10684867, PubMed:17051221, PubMed:17613531, PubMed:18986166, PubMed:19321446, PubMed:21098034, PubMed:2293021, PubMed:23922390, PubMed:24847884, PubMed:26394692, PubMed:26968463, PubMed:29596046). Substrate binding induces important conformation changes, making it possible to bind and degrade larger substrates, such as insulin (PubMed:23922390, PubMed:26394692, PubMed:29596046). Contributes to the regulation of peptide hormone signaling cascades and regulation of blood glucose homeostasis via its role in the degradation of insulin, glucagon and IAPP (By similarity). Plays a role in the degradation and clearance of APP-derived amyloidogenic peptides that are secreted by neurons and microglia (Probable) (PubMed:26394692, PubMed:9830016). Degrades the natriuretic peptides ANP, BNP and CNP, inactivating their ability to raise intracellular cGMP (PubMed:21098034). Also degrades an aberrant frameshifted 40-residue form of NPPA (fsNPPA) which is associated with familial atrial fibrillation in heterozygous patients (PubMed:21098034). Involved in antigen processing. Produces both the N terminus and the C terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is presented to cytotoxic T lymphocytes by MHC class I.(Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).

Alternative names

Insulin-degrading enzyme, Abeta-degrading protease, Insulin protease, Insulysin, Insulinase, IDE

Recommended products

Rabbit Recombinant Monoclonal Insulin degrading enzyme / IDE antibody - conjugated to HRP. Suitable for WB and reacts with Human samples.

Key facts

Isotype

IgG

Conjugation

HRP

Form

Liquid

Clonality

Monoclonal

Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number

EPR6099

Purification technique

Affinity purification Protein A

Concentration
Loading...

Storage

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Stable for 12 months at -20°C, Store in the dark

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Insulin degrading enzyme (IDE) also known as insulinase is a zinc metalloprotease involved in the breakdown of small proteins including insulin. IDE has a molecular weight of approximately 110 kDa. It works by cleaving the peptide bonds of its substrate proteins therefore decreasing their molecular integrity. IDE is expressed in several tissues including the liver muscle and kidney where it plays a significant role in regulating metabolic processes. This protein can be found both within cells and in the extracellular space.

Biological function summary

IDE manages the levels of insulin and other peptides by degrading them preventing accumulation and maintaining homeostasis. It is not part of a complex but it acts individually in cellular environments to modulate the concentration of its substrates. IDE is important for controlling insulin availability and turnover which impacts glucose metabolism. By influencing the degradation of insulin IDE aids in balancing metabolic demands with insulin availability.

Pathways

IDE plays a vital role in insulin signaling and glucose metabolic processes. It is directly involved in the insulin signaling pathway by regulating insulin levels which consequently affects cellular responses to insulin. IDE connects with several proteins associated with these pathways including insulin receptor and glucose transporters ensuring proper cell signaling and metabolic functions. By modulating insulin levels IDE helps optimize glucose uptake and storage.

Associated diseases and disorders

IDE has a relevant connection to Alzheimer's disease and type 2 diabetes. Its role in insulin degradation links it to type 2 diabetes where dysregulation of insulin levels can exacerbate the disease. IDE is also associated with Alzheimer's disease since it degrades amyloid-beta peptides. Any malfunction or altered expression of IDE can lead to accumulation of these peptides contributing to Alzheimer's pathology. In the context of these diseases IDE interacts with amyloid-beta precursor protein and components of insulin signaling pathways highlighting its significance in maintaining health and preventing disease progression.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (ab201836), expandable thumbnail

    Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (ab201836)

    ab201836 was shown to specifically react with Insulin degrading enzyme / IDE in wild-type HAP1 cells as signal was lost in IDE (Insulin degrading enzyme / IDE) knockout cells. Wild-type and IDE (Insulin degrading enzyme / IDE) knockout samples were subjected to SDS-PAGE. ab201836 and Alexa Fluor® 680 Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/5000 dilution and 1/20000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.

    All lanes: Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (ab201836) at 1/5000 dilution

    Lane 1: Wild-type HAP1 whole cell lysate at 20 µg

    Lane 2: IDE (Insulin degrading enzyme / IDE) knockout HAP1 whole cell lysate at 20 µg

    Predicted band size: 118 kDa

    Observed band size: 118 kDa

    Exposure time: 20min

  • Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (ab201836), expandable thumbnail

    Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (ab201836)

    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab201836 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.

    All lanes: Western blot - HRP Anti-Insulin degrading enzyme / IDE antibody [EPR6099] (ab201836) at 1/5000 dilution

    Lane 1: HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg

    Lane 2: HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate at 10 µg

    Lane 3: A375 (Human melanoma cell line) Whole Cell Lysate at 10 µg

    Lane 4: K562 (Human erythromyeloblastoid leukemia cell line) Nuclear Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 118 kDa

    Observed band size: 118 kDa

    Exposure time: 30s

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com